205 related articles for article (PubMed ID: 21435433)
1. Somatic mutations of PPP2R1A in ovarian and uterine carcinomas.
Shih IeM; Panuganti PK; Kuo KT; Mao TL; Kuhn E; Jones S; Velculescu VE; Kurman RJ; Wang TL
Am J Pathol; 2011 Apr; 178(4):1442-7. PubMed ID: 21435433
[TBL] [Abstract][Full Text] [Related]
2. PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
Rahman M; Nakayama K; Rahman MT; Nakayama N; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Otsuki Y; Nakayama S; Miyazaki K
Anticancer Res; 2013 Jan; 33(1):113-8. PubMed ID: 23267135
[TBL] [Abstract][Full Text] [Related]
3. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas.
McConechy MK; Anglesio MS; Kalloger SE; Yang W; Senz J; Chow C; Heravi-Moussavi A; Morin GB; Mes-Masson AM; ; Carey MS; McAlpine JN; Kwon JS; Prentice LM; Boyd N; Shah SP; Gilks CB; Huntsman DG
J Pathol; 2011 Apr; 223(5):567-73. PubMed ID: 21381030
[TBL] [Abstract][Full Text] [Related]
4. Mutation of PPP2R1A: a new clue in unveiling the pathogenesis of uterine serous carcinoma.
Shih IeM; Wang TL
J Pathol; 2011 May; 224(1):1-4. PubMed ID: 21432855
[TBL] [Abstract][Full Text] [Related]
5. PPP2R1A mutations are common in the serous type of endometrial cancer.
Nagendra DC; Burke J; Maxwell GL; Risinger JI
Mol Carcinog; 2012 Oct; 51(10):826-31. PubMed ID: 21882256
[TBL] [Abstract][Full Text] [Related]
6. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma.
Guan B; Mao TL; Panuganti PK; Kuhn E; Kurman RJ; Maeda D; Chen E; Jeng YM; Wang TL; Shih IeM
Am J Surg Pathol; 2011 May; 35(5):625-32. PubMed ID: 21412130
[TBL] [Abstract][Full Text] [Related]
7. Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics.
Prat J; D'Angelo E; Espinosa I
Hum Pathol; 2018 Oct; 80():11-27. PubMed ID: 29944973
[TBL] [Abstract][Full Text] [Related]
8. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
9. The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.
Le Gallo M; Rudd ML; Urick ME; Hansen NF; ; Merino MJ; Mutch DG; Goodfellow PJ; Mullikin JC; Bell DW
Cancer; 2018 Jan; 124(1):65-73. PubMed ID: 28940304
[TBL] [Abstract][Full Text] [Related]
10. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
Obata K; Morland SJ; Watson RH; Hitchcock A; Chenevix-Trench G; Thomas EJ; Campbell IG
Cancer Res; 1998 May; 58(10):2095-7. PubMed ID: 9605750
[TBL] [Abstract][Full Text] [Related]
11. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.
Kuhn E; Wu RC; Guan B; Wu G; Zhang J; Wang Y; Song L; Yuan X; Wei L; Roden RB; Kuo KT; Nakayama K; Clarke B; Shaw P; Olvera N; Kurman RJ; Levine DA; Wang TL; Shih IeM
J Natl Cancer Inst; 2012 Oct; 104(19):1503-13. PubMed ID: 22923510
[TBL] [Abstract][Full Text] [Related]
12. Infrequent mutations of the PPP2R1A and PPP2R1B genes in patients with ovarian cancer.
Wang F; Zou Y; Liu FY; Yu XH; Huang H; Zhang N; Qi YY; Liu RF; Liu XY; Chen J; Huang OP; He M
Mol Med Rep; 2013 Jun; 7(6):1826-30. PubMed ID: 23588898
[TBL] [Abstract][Full Text] [Related]
13. RNF43 mutations are recurrent in Chinese patients with mucinous ovarian carcinoma but absent in other subtypes of ovarian cancer.
Zou Y; Wang F; Liu FY; Huang MZ; Li W; Yuan XQ; Huang OP; He M
Gene; 2013 Nov; 531(1):112-6. PubMed ID: 24001777
[TBL] [Abstract][Full Text] [Related]
14. Histotype-genotype correlation in 36 high-grade endometrial carcinomas.
Hoang LN; McConechy MK; Köbel M; Han G; Rouzbahman M; Davidson B; Irving J; Ali RH; Leung S; McAlpine JN; Oliva E; Nucci MR; Soslow RA; Huntsman DG; Gilks CB; Lee CH
Am J Surg Pathol; 2013 Sep; 37(9):1421-32. PubMed ID: 24076778
[TBL] [Abstract][Full Text] [Related]
15. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
16. Patient derived mutation W257G of PPP2R1A enhances cancer cell migration through SRC-JNK-c-Jun pathway.
Jeong AL; Han S; Lee S; Su Park J; Lu Y; Yu S; Li J; Chun KH; Mills GB; Yang Y
Sci Rep; 2016 Jun; 6():27391. PubMed ID: 27272709
[TBL] [Abstract][Full Text] [Related]
17. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of undifferentiated carcinoma associated with endometrioid carcinoma.
Kuhn E; Ayhan A; Bahadirli-Talbott A; Zhao C; Shih IeM
Am J Surg Pathol; 2014 May; 38(5):660-5. PubMed ID: 24451280
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical expression of wilms tumor gene protein in different histologic subtypes of ovarian carcinomas.
Waldstrøm M; Grove A
Arch Pathol Lab Med; 2005 Jan; 129(1):85-8. PubMed ID: 15628914
[TBL] [Abstract][Full Text] [Related]
20. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma.
Gemignani ML; Schlaerth AC; Bogomolniy F; Barakat RR; Lin O; Soslow R; Venkatraman E; Boyd J
Gynecol Oncol; 2003 Aug; 90(2):378-81. PubMed ID: 12893203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]